Exchange: NASDAQ·Updated 06:46 PM EDT

MMSI News

News
all
press releases
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.
Zacks
More News
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
Zacks
Neil Peterson Executes Sell Order: Offloads $678K In Merit Medical Systems Stock
Neil Peterson, Chief Operating Officer at Merit Medical Systems (NASDAQ:MMSI), disclosed an insider sell on August 25, according to a recent SEC filing. What Happened: A Form 4 filing from the U.S. Securities andread more...
Benzinga
Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
Merit Medical's growth case is strengthening as launches, acquisitions and therapeutic products broaden its mix, but its premium valuation raises the execution bar.
Zacks
Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?
Merit Medical's 22.2% monthly rally gains support from stronger Q2 growth and a raised 2026 outlook, but valuation and tariff risks remain.
Zacks
COO vs. MMSI: Which Stock Is the Better Value Option?
COO vs. MMSI: Which Stock Is the Better Value Option?
Zacks
Here's Why Merit Medical (MMSI) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
COO vs. MMSI: Which Stock Should Value Investors Buy Now?
COO vs. MMSI: Which Stock Is the Better Value Option?
Zacks
MMSI Q2 Earnings & Revenues Beat Estimates, '26 Guidance Raised
Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.
Zacks
These Analysts Increase Their Forecasts On Merit Medical Systems After Strong Q2 Results
Merit Medical Systems Inc (NASDAQ: MMSI) reported strong Q2 earnings, beating estimates with raised guidance. Analysts maintain Buy ratings with increased price targets.read more...
Benzinga

Advertisement|Remove ads.